BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

GC Biopharma and Novelty Nobility Join Forces to Develop New Antibody Therapy for Geographic Atrophy in Age-Related Macular Degeneration

GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeut...

October 29, 2024 | News

South Korea’s Qurient Launches Phase 1 Clinical Trial for Adrixetinib in AML Following FDA IND Clearance

Qurient has announced the commencement of a clinical trial for adrixetinib (formerly named Q702), following the clearance of its investigational new drug (...

October 25, 2024 | News

EpiVax and CUBRC Secure $2M FDA Contract to Develop T Cell Assay Standards for Generic Drug Immunogenicity

EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the...

October 25, 2024 | News

Australia's Telix Pharmaceuticals Secures FDA Priority Review for Pixclara® (TLX101-CDx) Glioma Imaging Agent

Telix Pharmaceuticals announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ...

October 24, 2024 | News

RAPT Therapeutics Boosts Drug Development Efficiency with INTEGRA Biosciences’ Pipettes for Cancer and Inflammatory Disease Research

RAPT Therapeutics in San Francisco, USA, relies on INTEGRA Biosciences’ pipettes to seamlessly accelerate the development of its candidate small...

October 23, 2024 | News

Angelini Pharma Secures Global and Asia Licensing Option for Brain Health Compound CV-01 in Partnership with Cureverse

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel...

October 23, 2024 | News

Everest Medicines Gains TFDA Approval for NEFECON® to Treat IgA Nephropathy in Taiwan

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...

October 21, 2024 | News

Eisai and Biogen to Seek Reconsideration After TGA Declines Initial Approval of Lecanemab for Early Alzheimer’s Treatment in Australia

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial de...

October 18, 2024 | News

Antengene’s XPOVIO® Gains Third Approval in South Korea for Multiple Myeloma Treatment

This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug in South...

October 18, 2024 | News

Alphamab Oncology and CSPC Pharmaceutical's Phase III Trial of KN026 for HER2-Positive Breast Cancer Receives Approval from NMPA

Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an applicat...

October 17, 2024 | News

PharmAbcine Receives Safety Approval for 4mg Dose in Phase 1 Trial of PMC-403, Paving the Way for Multiple Ascending Dose Study

Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. ...

October 15, 2024 | News